Rexgenero is a leading regenerative medicine company and developer of advanced cell-based therapeutics for the treatment of serious diseases that are poorly treated with existing therapies. We are conducting clinical trials with our cellular therapies with the intention of obtaining marketing authorization in Europe, the United States and other markets.
Our lead candidate REX-001 is a highly innovative autologous cell therapy that is being studied in two Phase III clinical trials in patients with Critical Limb Ischemia (CLI) with diabetes. CLI is a poorly treated disease with approx. 25% of patients requiring amputation of the affected limb and the mortality rate of patients diagnosed with CLI is of 20-25% in the first year. The Phase III clinical studies aim to confirm the highly encouraging results seen in three Phase II trials where the majority of patients experienced a significant improvement in their clinical condition following treatment with REX-001.
Our treatments draw on an exceptional understanding of the fundamental science of cell therapies. Our current cell therapies have been developed by the Andalusian Health Authority (Servicio Andaluz de Salud) and Andalusian Initiative of Advanced Therapies and we aim to work with them to develop further cell therapies to treat other indications with high unmet medical needs.